Search This Blog

Tuesday, August 11, 2026

Prelude Therapeutics beats, says $155M cash funds operations into Q2 2028

 

Prelude Therapeutics beats Q2 2026 estimates with EPS -$0.14 and revenue $5.7M, says $155M cash funds operations into Q2 2028

  • Non-GAAP EPS of -$0.14 in fiscal Q2 2026 improved 66% year over year.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)